<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Quality Measures Clearinghouse (NQMC).</xmlsource><Section SecID="560" OrdBy="10" Name="General"><Field FieldID="11" OrdBy="20" ID="561" Name="Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Stroke and transient ischaemic attack (TIA): the percentage of patients with a stroke shown to be non-haemorrhagic or a history of TIA who have a record in the preceding 12 months that an anti-platelet agent or an anti-coagulant is being taken.&lt;/div&gt;" /></Field><Field FieldID="1" OrdBy="30" ID="562" Name="Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;British Medical Association (BMA) and NHS Employers. 2014/15 general medical services (GMS) contract quality and outcomes framework (QOF): guidance for GMS contract 2014/15. London (UK): British Medical Association, National Health Service Confederation; 2014 Mar. 182 p. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Unspecified transient cerebral ischemia  (435.9)"/><FieldValue Value="MSH: Anticoagulants ; Aspirin ; Dipyridamole ; Drug Therapy, Combination ; Ischemic Attack, Transient ; Platelet Aggregation Inhibitors ; Stroke ; Ticlopidine "/><FieldValue Value="MTH: Anticoagulants ; Aspirin ; Cerebrovascular accident ; Combination Drug Therapy ; Dipyridamole ; Platelet Aggregation Inhibitors ; Transient Cerebral Ischemia ; Transient Ischemic Attack "/><FieldValue Value="PDQ: acetylsalicyclic acid ; dipyridamole "/><FieldValue Value="SNOMEDCT_US: Anticoagulant ; Antiplatelet agent ; Aspirin ; Cerebrovascular accident ; Clopidogrel ; Dipyridamole ; Ticlopidine ; Transient cerebral ischemia "/></Field></Section><Section SecID="563" OrdBy="40" Name="Measure Domain"><Field FieldID="3025" OrdBy="50" ID="564" Name="Primary Measure Domain" Type="picklist-one"><FieldValue Value="Clinical Quality Measures: Process" /></Field><Field FieldID="3026" OrdBy="60" ID="565" Name="Secondary Measure Domain" Type="picklist-one"><FieldValue Value="Does not apply to this measure" /></Field></Section><Section SecID="566" OrdBy="70" Name="Brief Abstract"><Field FieldID="34" OrdBy="80" ID="567" Name="Description" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This measure is used to assess the percentage of patients with a stroke shown to be non-haemorrhagic or a history of transient ischaemic attack (TIA) who have a record in the preceding 12 months that an anti-platelet agent or an anti-coagulant is being taken. &lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="21" OrdBy="90" ID="568" Name="Rationale" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Stroke is the third most common cause of death in the developed world. One quarter of stroke deaths occur under the age of 65. There is evidence that appropriate diagnosis and management can improve outcomes.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Long-term anti-platelet therapy reduces the risk of serious vascular events following a stroke by about a quarter. It is advised that anti-platelet therapy is prescribed for the secondary prevention of recurrent stroke and other vascular events in patients who have sustained an ischaemic cerebrovascular event.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The British National Formulary (BNF) (2011) makes the following recommendations: &lt;/p&gt;&#xD;&#xA;&lt;blockquote&gt;&#xD;&#xA;&lt;p&gt;&quot;Following a transient ischaemic attack (TIA), long-term treatment with modified-release dipyridamole 200 mg twice daily in combination with aspirin 75 mg once daily is recommended. If patients are intolerant of aspirin, or it is contra-indicated, then modified-release dipyridamole alone is recommended. If patients are intolerant of dipyridamole, or it is contraindicated, then aspirin alone is recommended. Patients who are intolerant of both aspirin and dipyridamole should receive clopidogrel alone (unlicensed use). &lt;/p&gt;&#xD;&#xA;&lt;p&gt;Following an ischaemic stroke (not associated with atrial fibrillation [AF] &amp;ndash; see below), long-term treatment with clopidogrel 75 mg once daily is recommended. If clopidogrel is contraindicated or not tolerated, patients should receive modified-release dipyridamole 200 mg twice daily in combination with aspirin 75 mg once daily. If both aspirin and clopidogrel are contraindicated or not tolerated, then modified-release dipyridamole alone is recommended. If both dipyridamole and clopidogrel are contraindicated or not tolerated, than aspirin alone is recommended.&quot; &lt;/p&gt;&#xD;&#xA;&lt;/blockquote&gt;&#xD;&#xA;&lt;p&gt;It is advised that patients with stroke associated with AF are reviewed for long-term treatment with warfarin or an alternative anti-coagulant (see the &lt;a href=&quot;/browse/by-organization-indiv.aspx?orgid=1783&amp;amp;objid=26039&quot; title=&quot;Atrial Fibrillation Measure Set&quot;&gt;Atrial Fibrillation indicator set&lt;/a&gt;). &lt;/p&gt;&#xD;&#xA;&lt;p&gt;Refer to National Institute for Health and Care Excellence (NICE) Technology Appraisal (TA 210), &quot;Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of TA 90),&quot; (2010) for further information.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="3500" OrdBy="100" ID="569" Name="Evidence for Rationale" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;British Medical Association (BMA) and NHS Employers. 2014/15 general medical services (GMS) contract quality and outcomes framework (QOF): guidance for GMS contract 2014/15. London (UK): British Medical Association, National Health Service Confederation; 2014 Mar. 182 p. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;British Medical Association (BMA), Royal Pharmaceutical Society. British National Formulary (BNF). Edition 62. London (UK): Royal Pharmaceutical Society; 2011 Sep. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="3022" OrdBy="110" ID="570" Name="Primary Health Components" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Stroke (non-haemorrhagic); transient ischaemic attack (TIA); anti-platelet agent; anti-coagulant&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="23" OrdBy="120" ID="571" Name="Denominator Description" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Patients with a stroke shown to be non-haemorrhagic or a history of transient ischaemic attack (TIA) (see the related &quot;Denominator Inclusions/Exclusions&quot; field)&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="24" OrdBy="130" ID="572" Name="Numerator Description" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Number of patients from the denominator who have a record in the preceding 12 months that an anti-platelet agent or an anti-coagulant is being taken &lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="573" OrdBy="140" Name="Evidence Supporting the Measure"><Field FieldID="3027" OrdBy="150" ID="574" Name="Type of Evidence Supporting the Criterion of Quality for the Measure" Type="picklist-choice"><FieldValue Value="A clinical practice guideline or other peer-reviewed synthesis of the clinical research evidence" /><FieldValue Value="A formal consensus procedure, involving experts in relevant clinical, methodological,  public health and organizational sciences" /></Field><Field FieldID="3501" OrdBy="160" ID="575" Name="Additional Information Supporting Need for the Measure" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Unspecified&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="3072" OrdBy="180" ID="577" Name="Extent of Measure Testing" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Unspecified&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="580" OrdBy="210" Name="State of Use of the Measure"><Field FieldID="3029" OrdBy="220" ID="581" Name="State of Use" Type="picklist-one"><FieldValue Value="Current routine use" /></Field><Field FieldID="3030" OrdBy="230" ID="582" Name="Current Use" Type="picklist-choice-3"><FieldValue Value="not defined yet" /></Field></Section><Section SecID="583" OrdBy="240" Name="Application of the Measure in its Current Use"><Field FieldID="3031" OrdBy="250" ID="584" Name="Measurement Setting" Type="picklist-choice"><FieldValue Value="Ambulatory/Office-based Care" /></Field><Field FieldID="3032" OrdBy="260" ID="585" Name="Professionals Involved in Delivery of Health Services" Type="picklist-choice-3"><FieldValue Value="not defined yet" /></Field><Field FieldID="3033" OrdBy="270" ID="586" Name="Least Aggregated Level of Services Delivery Addressed" Type="picklist-one"><FieldValue Value="Clinical Practice or Public Health Sites" /></Field><Field FieldID="3505" OrdBy="280" ID="587" Name="Statement of Acceptable Minimum Sample Size" Type="picklist-one"><FieldValue Value="Unspecified" /></Field><Field FieldID="41" OrdBy="290" ID="588" Name="Target Population Age" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Unspecified&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="42" OrdBy="300" ID="589" Name="Target Population Gender" Type="picklist-one"><FieldValue Value="Either male or female" /></Field></Section><Section SecID="660" OrdBy="310" Name="National Strategy for Quality Improvement in Health Care"><Field FieldID="3522" OrdBy="320" ID="661" Name="National Quality Strategy Aim" Type="text"><FieldValue Value="&lt;ul&gt;&lt;li&gt;Better Care&lt;/li&gt;&lt;/ul&gt;" /></Field><Field FieldID="3525" OrdBy="330" ID="662" Name="National Quality Strategy Priority" Type="text"><FieldValue Value="&lt;ul&gt;&lt;li&gt;Prevention and Treatment of Leading Causes of Mortality&lt;/li&gt;&lt;/ul&gt;" /></Field></Section><Section SecID="590" OrdBy="340" Name="Institute of Medicine (IOM) National Health Care Quality Report Categories"><Field FieldID="3163" OrdBy="350" ID="591" Name="IOM Care Need" Type="picklist-choice"><FieldValue Value="Getting Better" /><FieldValue Value="Living with Illness" /></Field><Field FieldID="3164" OrdBy="360" ID="592" Name="IOM Domain" Type="picklist-choice"><FieldValue Value="Effectiveness" /></Field></Section><Section SecID="593" OrdBy="370" Name="Data Collection for the Measure"><Field FieldID="3506" OrdBy="380" ID="594" Name="Case Finding Period" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The reporting year&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="3054" OrdBy="390" ID="595" Name="Denominator Sampling Frame" Type="picklist-one"><FieldValue Value="Patients associated with provider" /></Field><Field FieldID="3057" OrdBy="400" ID="598" Name="Denominator (Index) Event or Characteristic" Type="picklist-choice"><FieldValue Value="Clinical Condition" /></Field><Field FieldID="3058" OrdBy="410" ID="599" Name="Denominator Time Window" Type="picklist-choice-3"><FieldValue Value="not defined yet" /></Field><Field FieldID="55" OrdBy="420" ID="596" Name="Denominator Inclusions/Exclusions" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Inclusions&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;Patients with a stroke shown to be non-haemorrhagic or a history of transient ischaemic attack (TIA)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Exclusions&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;Unspecified&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Note&lt;/strong&gt;: Exception reporting applies to indicators in any domain of the Quality and Outcomes Framework (QOF), where the achievement is determined by the percentage of patients receiving the specified level of care.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&quot;Exceptions&quot; relate to registered patients who are on the relevant disease register or in the target population group and would ordinarily be included in the indicator denominator, but who are excepted by the contractor on the basis of one or more of the exception criteria. Patients are removed from the denominator and numerator for an indicator if they have been both excepted and they have not received the care specified in the indicator wording. If the patient has been excepted but subsequently the care has been carried out within the relevant time period, the patient will be included in both the denominator and the numerator (achievement will always override an exception).&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;Patients may be excepted if they fall within the strict criteria detailed below:&lt;/p&gt;&#xD;&#xA;&lt;ol class=&quot;Note&quot; style=&quot;list-style-type: upper-alpha;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Patients who have been recorded as refusing to attend review who have been invited on at least three occasions during the financial year to which the achievement payments relate (except in the case of indicator CS002, where the patient should have been invited on at least three occasions during the period of time specified in the indicator during which achievement is to be measured [e.g., the preceding five years ending on 31 March in the financial year to which achievement payments relate]). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients for whom it is not appropriate to review the chronic disease parameters due to particular circumstances, for example, a patient who has a terminal illness or is extremely frail. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients newly diagnosed or who have recently registered with the contractor who should have measurements made within three months and delivery of clinical standards within nine months, e.g., blood pressure or cholesterol measurements within target levels. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients who are on maximum tolerated doses of medication whose levels remain sub-optimal. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients for whom prescribing a medication is not clinically appropriate, e.g., those who have an allergy, contraindication or have experienced an adverse reaction. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Where a patient has not tolerated medication. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Where a patient does not agree to investigation or treatment (informed dissent) and this has been recorded in their patient record following a discussion with the patient. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Where the patient has a supervening condition which makes treatment of their condition inappropriate, e.g., cholesterol reduction where the patient has liver disease. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Where an investigative service or secondary care service is unavailable. &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;Refer to the original measure documentation for further details.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="3507" OrdBy="430" ID="597" Name="Exclusions/Exceptions" Type="picklist-choice-4"><FieldValue Value="not defined yet" /></Field><Field FieldID="59" OrdBy="440" ID="600" Name="Numerator Inclusions/Exclusions" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Inclusions&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;Number of patients from the denominator who have a record in the preceding 12 months that an anti-platelet agent or an anti-coagulant is being taken&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Exclusions&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;Unspecified&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="3061" OrdBy="450" ID="601" Name="Numerator Search Strategy" Type="picklist-one"><FieldValue Value="Fixed time period or point in time" /></Field><Field FieldID="3062" OrdBy="460" ID="602" Name="Data Source" Type="picklist-many"><FieldValue Value="Electronic health/medical record" /><FieldValue Value="Paper medical record" /><FieldValue Value="Registry data" /></Field><Field FieldID="3065" OrdBy="470" ID="603" Name="Type of Health State" Type="picklist-one"><FieldValue Value="Does not apply to this measure" /></Field><Field FieldID="3066" OrdBy="480" ID="604" Name="Instruments Used and/or Associated with the Measure" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Unspecified&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="605" OrdBy="490" Name="Computation of the Measure"><Field FieldID="3508" OrdBy="500" ID="606" Name="Measure Specifies Disaggregation" Type="picklist-one"><FieldValue Value="Does not apply to this measure" /></Field><Field FieldID="3067" OrdBy="520" ID="608" Name="Scoring" Type="picklist-many"><FieldValue Value="Rate/Proportion" /></Field><Field FieldID="3068" OrdBy="530" ID="609" Name="Interpretation of Score" Type="picklist-one"><FieldValue Value="Desired value is a higher score" /></Field><Field FieldID="3090" OrdBy="540" ID="610" Name="Allowance for Patient or Population Factors" Type="picklist-choice-3"><FieldValue Value="not defined yet" /></Field><Field FieldID="3070" OrdBy="560" ID="612" Name="Standard of Comparison" Type="picklist-choice-3"><FieldValue Value="not defined yet" /></Field><Field FieldID="71" OrdBy="570" ID="613" Name="Prescriptive Standard" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Achievement thresholds: 57% to 97%&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="9" OrdBy="580" ID="614" Name="Evidence for Prescriptive Standard" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;British Medical Association (BMA) and NHS Employers. 2014/15 general medical services (GMS) contract quality and outcomes framework (QOF): guidance for GMS contract 2014/15. London (UK): British Medical Association, National Health Service Confederation; 2014 Mar. 182 p. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field></Section><Section SecID="615" OrdBy="590" Name="Identifying Information"><Field FieldID="73" OrdBy="600" ID="616" Name="Original Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;STIA007. The percentage of patients with a stroke shown to be non-haemorrhagic, or a history of TIA, who have a record in the preceding 12 months that an anti-platelet agent, or an anti-coagulant is being taken.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="74" OrdBy="610" ID="617" Name="Measure Collection Name" Type="text"><FieldValue Value="Quality and Outcomes Framework Indicators" /></Field><Field FieldID="75" OrdBy="620" ID="618" Name="Measure Set Name" Type="text"><FieldValue Value="Stroke and TIA (STIA)" /></Field><Field FieldID="16" OrdBy="650" ID="621" Name="Submitter" Type="orglist"><FieldValue Value="British Medical Association - Medical Specialty Society" /><FieldValue Value="National Health Service (NHS) Confederation - National Government Agency [Non-U.S.]" /></Field><Field FieldID="17" OrdBy="660" ID="622" Name="Developer" Type="orglist-p"><FieldValue Value="British Medical Association - Medical Specialty Society" /><FieldValue Value="National Health Service (NHS) Confederation - National Government Agency [Non-U.S.]" /></Field><Field FieldID="79" OrdBy="670" ID="623" Name="Funding Source(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The expert panel who developed the indicators were funded by the English Department of Health.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="80" OrdBy="680" ID="624" Name="Composition of the Group that Developed the Measure" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The main indicator development group is based in the National Primary Care Research and Development Centre in the University of Manchester. They are: Professor Helen Lester, NPCRDC, MB, BCH, MD; Dr. Stephen Campbell, NPCRDC, PhD; Dr. Umesh Chauhan, NPCRDC, MB, BS, PhD.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Others involved in the development of individual indicators are: Professor Richard Hobbs, Dr. Richard McManus, Professor Jonathan Mant, Dr. Graham Martin, Professor Richard Baker, Dr. Keri Thomas, Professor Tony Kendrick, Professor Brendan Delaney, Professor Simon De Lusignan, Dr. Jonathan Graffy, Dr. Henry Smithson, Professor Sue Wilson, Professor Claire Goodman, Dr. Terry O'Neill, Dr. Philippa Matthews, Dr. Simon Griffin, Professor Eileen Kaner.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="81" OrdBy="690" ID="625" Name="Financial Disclosures/Other Potential Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None for the main indicator development group.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="82" OrdBy="700" ID="626" Name="Endorser" Type="orglist"><FieldValue Value="National Health Service - National Government Agency [Non-U.S.]" /></Field><Field FieldID="19" OrdBy="730" ID="629" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This measure was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="3086" OrdBy="740" ID="630" Name="Date of Most Current Version in NQMC" Type="date"><FieldValue Value="2014 Mar" /></Field><Field FieldID="3511" OrdBy="750" ID="631" Name="Measure Maintenance" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Unspecified&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="3512" OrdBy="760" ID="632" Name="Date of Next Anticipated Revision" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Unspecified&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="20" OrdBy="770" ID="633" Name="Measure Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the measure.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This measure updates a previous version: British Medical Association (BMA) and NHS Employers. Quality and outcomes framework guidance for GMS contract 2013/14. London (UK): British Medical Association, National Health Service Confederation; 2013 Mar. 203 p. &lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="14" OrdBy="780" ID="634" Name="Measure Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The individual measure, &quot;STIA007. The Percentage of Patients with a Stroke Shown to Be Non-haemorrhagic, or a History of TIA, Who Have a Record in the Preceding 12 Months That an Anti-platelet Agent, or an Anti-coagulant Is Being Taken,&quot; is published in the &quot;2014/15 General Medical Services (GMS) Contract Quality and Outcomes Framework (QOF): Guidance for GMS Contract 2014/15.&quot; This document is available from the &lt;a href=&quot;http://bma.org.uk/-/media/files/pdfs/practical%20advice%20at%20work/contracts/gpqofguidance2014-15.pdf&quot; title=&quot;BMA Web site&quot;&gt;British Medical Association Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="87" OrdBy="800" ID="636" Name="NQMC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NQMC summary was completed by ECRI on December 15, 2006. The information was verified by the measure developer on April 26, 2007. &lt;/p&gt;&#xD;&#xA;&lt;p&gt;This NQMC summary was updated by ECRI Institute on January 7, 2009. The information was verified by the measure developer on February 9, 2009. &lt;/p&gt;&#xD;&#xA;&lt;p&gt;This NQMC summary was updated by ECRI Institute on September 25, 2009. The information was verified by the measure developer on March 4, 2010. &lt;/p&gt;&#xD;&#xA;&lt;p&gt;This NQMC summary was retrofitted into the new template on June 22, 2011. &lt;/p&gt;&#xD;&#xA;&lt;p&gt;This NQMC summary was updated by ECRI Institute on August 27, 2013 and again on July 22, 2014.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="88" OrdBy="810" ID="637" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;No copyright restrictions apply.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="641" OrdBy="850" Name="Production"><Field FieldID="1" OrdBy="1366" ID="562" Name="Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;British Medical Association (BMA) and NHS Employers. 2014/15 general medical services (GMS) contract quality and outcomes framework (QOF): guidance for GMS contract 2014/15. London (UK): British Medical Association, National Health Service Confederation; 2014 Mar. 182 p. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NQMC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Quality Measures Clearinghouseâ„¢ (NQMC) does not develop, produce, approve, or endorse the measures represented on this site.&lt;/p&gt; &lt;p&gt;All measures summarized by NQMC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public and private organizations, other government agencies, health care organizations or plans, individuals, and similar entities.&lt;/p&gt; &lt;p&gt;Measures represented on the NQMC Web site are submitted by measure developers, and are screened solely to determine that they meet the NQMC Inclusion Criteria which may be found at &lt;a href=&quot;../about/inclusion-criteria.aspx&quot;&gt;http://www.qualitymeasures.ahrq.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &lt;p&gt;NQMC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or its reliability and/or validity of the quality measures and related materials represented on this site. Moreover, the views and opinions of developers or authors of measures represented on this site do not necessarily state or reflect those of NQMC, AHRQ, or its contractor, ECRI Institute, and inclusion or hosting of measures in NQMC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &lt;p&gt;Readers with questions regarding measure content are directed to contact the measure developer.&lt;/p&gt;" /></Field></Section></Version>
